← All trials
NCT03402295
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 15, 2009
- Primary completion
- Jun 15, 2014
- Completion date
- Oct 15, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 311
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Grupo de Estudos Multicentricos em Onco-HematologiaLead sponsor
- Federal University of BahiaOverall official - principal investigator
- Grupo de Estudos Multicentricos em Onco-HematologiaReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.